Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSA | P10619 | 7/20 | 0.46 |
| ▸ | KCNA5 | P22460 | 8/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 4/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21459425 | 1.00 | CTSA (0.46) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| SCHEMBL21459803 | 1.00 | CTSA (0.46) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| SCHEMBL29949515 | 1.00 | CTSA (0.46) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| SCHEMBL29949743 | 1.00 | CTSA (0.46) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL21459483 | 0.99 | CTSA (0.45) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL21459485 | 0.99 | CTSA (0.45) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| Hydrochloric Acid SCHEMBL29949806 | 0.99 | CTSA (0.45) | CTSAKCNA5FFAR1ROCK2ROCK1 | |
| SCHEMBL31303262 | 0.94 | CTSA (0.50) | CTSAKCNA5 | |
| SCHEMBL21459713 | 0.94 | CTSA (0.50) | CTSAKCNA5 | |
| SCHEMBL21459711 | 0.94 | CTSA (0.50) | CTSAKCNA5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3773573-B1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC INC (US) | 2026-03-18 | — | — | EP | disclosed |
| US-12221416-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2025-02-11 | — | — | US | disclosed |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2024-09-05 | — | — | US | disclosed |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2022-10-27 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | MORPHIC THERAPEUTIC, INC. (US) | 2021-11-16 | — | — | US | disclosed |
| EP-3773573-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | Morphic Therapeutic, Inc. (US) | 2021-02-17 | — | — | EP | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2020-12-10 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-10759756-B2 | Antagonists of human integrin α4β7 | MORPHIC THERAPEUTIC, INC. (US) | 2020-09-01 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. | 2019-10-17 | — | — | US | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
| WO-2019200202-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | MORPHIC THERAPEUTIC, INC. (US) | 2019-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12221416-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | CTSA 1771/4885KCNA5 1297/4885FFAR1 2927/4885 |
| US-20190315692-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | CTSA 1442/4885KCNA5 1144/4885FFAR1 2643/4885 |
| US-20220340529-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | CTSA 1442/4885KCNA5 1144/4885FFAR1 2643/4885 |
| US-20240294475-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | CTSA 1442/4885KCNA5 1144/4885FFAR1 2643/4885 |
| US-11174228-B2 | Antagonists of human integrin (α4)(β7) | ITGB7, ITGB4, ITGA4 | CTSA 1690/4885KCNA5 1042/4885FFAR1 2655/4885 |
| US-20200385352-A1 | ANTAGONISTS OF HUMAN INTEGRIN (ALPHA4)(BETA7) | ITGB7, ITGB4, ITGA4 | CTSA 1442/4885KCNA5 1144/4885FFAR1 2643/4885 |
| US-10759756-B2 | Antagonists of human integrin α4β7 | ITGB7, ITGB4, ITGA4 | CTSA 1771/4885KCNA5 1297/4885FFAR1 2927/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.